>>306 ソースはこれですか?

China's NMPA Approves Tocilizumab Biosimilar
January 17, 2023

The China National Medical Products Administration (NMPA) approved Bio-Thera Solutions’ tocilizumab biosimilar (BAT1806) referencing Actemra for the treatment of several rheumatic conditions.

https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar